Fantastic updates about treating intermediate-risk neuroblastoma – St. Baldrick’s Foundation
St. Baldrick’s Foundation shared a post on LinkedIn:
Exciting Update on Neuroblastoma Treatment!
Researchers involved in a St. Baldrick’s supported, Children’s Oncology Group clinical trial have some fantastic updates about treating intermediate-risk neuroblastoma. Here’s the scoop:
What They Did:
They treated 404 kids using a special plan based on the cancer’s biology and how it responded to initial treatment. Initial results already reported excellent 3-year survival. Here are the long-term (10-year) results:
10-Year Event-Free Survival: 82%
10-Year Overall Survival: 95%
Key Takeaway:
The treatment plan from the ANBL0531 COG study shows excellent long-term survival for most kids. However, better treatments are still needed for those with tougher cancer types.”
Additional information
Source: St. Baldrick’s Foundation/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023